An interventional study of iNAD CONTROL and Placebo in Glaucoma, sponsored by Fondazione G.B. Bietti, IRCCS. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Fondazione G.B. Bietti, IRCCS · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn whether a daily dietary supplement called iNAD CONTROL can improve the function of the retinal ganglion cells (the nerve cells of the retina that carry visual information to the brain) in adults with open-angle glaucoma who are already being treated with eye-pressure-lowering therapy. iNAD CONTROL contains nicotinamide riboside (a form of vitamin B3), acetyl-L-carnitine, forskolin and hesperidin, which may support the energy metabolism of these nerve cells and protect them from damage.
The main question it aims to answer is:
- Does taking iNAD CONTROL for 12 weeks improve retinal ganglion cell function, measured with an electroretinogram (ERG, a test that records the electrical response of the retina to light), compared with a placebo (a look-alike tablet with no active ingredients)?
Researchers will also look at whether iNAD CONTROL changes the visual field, the thickness of the retinal nerve fiber layers measured with optical coherence tomography (OCT), visual acuity and eye pressure.
Researchers will compare iNAD CONTROL with placebo. Each participant will receive both: iNAD CONTROL for 12 weeks and placebo for 12 weeks, in a random order. Neither the participants nor the study doctors will know which product is being taken in each period.
Participants will:
BACKGROUND Glaucoma is characterized by progressive dysfunction and loss of retinal ganglion cells (RGCs) and their axons. Oxidative stress and mitochondrial dysfunction are increasingly recognized as key mechanisms underlying RGC degeneration. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor for mitochondrial ATP production and for NAD+-dependent enzymes that regulate cellular stress responses and survival. Patients with primary open-angle glaucoma have been shown to have reduced circulating levels of nicotinamide, a major NAD+ precursor, and preclinical studies have shown that raising retinal NAD+ levels protects RGCs and preserves retinal function in experimental glaucoma. Objective electrophysiological measures of inner retinal function, in particular the photopic negative response (PhNR) of the full-field electroretinogram (ERG), can detect short-term changes in RGC-related function and are suitable for interventional studies in which structural or perimetric changes are expected to be modest over a period of months.
RATIONALE This study evaluates RGC function in response to oral supplementation with nicotinamide riboside and acetyl-L-carnitine, compounds that support energy metabolism (direct neuroprotection), combined with forskolin and hesperidin, natural antioxidants that may support IOP-lowering therapy (indirect neuroprotection). Nicotinamide riboside and acetyl-L-carnitine together support the synthesis of acetyl-coenzyme A, and therefore of ATP and acetylcholine, even under the conditions of impaired glycolysis observed in glaucoma. Forskolin and hesperidin may help counteract sudden, transient increases in IOP despite hypotensive therapy. The combination is administered as the dietary supplement iNAD CONTROL.
STUDY DESIGN
Interventional, national, multicentre, prospective, double-masked, randomized, placebo-controlled 2x2 cross-over trial. Sixty adults with treated open-angle glaucoma (mean deviation between -3.0 and -12.0 dB) and stable IOP below 18 mmHg will be enrolled and randomized 1:1 to one of two treatment sequences:
INTERVENTION iNAD CONTROL, 1 tablet per day orally for 12 weeks. Each tablet contains acetyl-L-carnitine hydrochloride 500 mg, nicotinamide riboside chloride 300 mg, Coleus forskohlii dry root extract titrated at 20% forskolin 75 mg (15 mg forskolin) and micronized hesperidin 50 mg.
Placebo: a food product free of functional ingredients, matched to the study product in appearance and organoleptic characteristics, 1 tablet per day orally for 12 weeks.
Standard glaucoma treatment continues unchanged. Other systemic or topical agents with potential neuroprotective effects (e.g., citicoline) are prohibited during the study.
RANDOMIZATION AND MASKING The randomization list is generated by an independent statistician using a computer-generated schedule with permuted blocks of variable size. Randomization is centralized through the electronic study database and occurs only after eligibility is confirmed at the baseline visit. Participants, investigators, outcome assessors, study coordinators, data managers and statisticians involved in the primary analysis remain masked to treatment allocation. Study products are packaged and labelled identically.
STUDY VISITS AND PROCEDURES Each participant attends 5 visits over 24 weeks: Week 0 (baseline/randomization), Week 6, Week 12 (end of Period 1 and cross-over), Week 18 and Week 24 (end of Period 2/end of study). At every visit the following are performed: best-corrected visual acuity (ETDRS letters or logMAR), slit-lamp biomicroscopy, Goldmann applanation tonometry, blood pressure, body weight, standard automated perimetry, photopic ERG, SD-OCT, adverse event recording, concomitant medication review and pill count for adherence.
One eye per participant is designated as the study eye; if both eyes are eligible, the eye with the better quality visual field at screening is selected.
STATISTICAL ANALYSIS The sample size was informed by a similar cross-over trial of nicotinamide in glaucoma (Hui et al., 2020). Enrolling 60 participants, allowing for approximately 20% attrition or unreliable ERG/visual field measurements, is expected to provide at least 48 evaluable participants and 80% power to detect a clinically meaningful difference in PhNRPT between treatment periods (two-sided alpha 0.05).
The primary analysis set includes participants with outcome data after both treatment periods; a per-protocol analysis includes adherent participants without major protocol deviations. The difference between iNAD CONTROL and placebo in change from baseline in PhNRPT after each 12-week period will be assessed with linear mixed models adjusting for baseline value, period and centre. Prespecified tests for carry-over and period effects will be performed; if clinically important carry-over is detected, a sensitivity analysis using first-period data only will be performed. Missing data will be handled with mixed models under a missing-at-random assumption, with multiple imputation and complete-case sensitivity analyses. Secondary endpoints will be analysed within the same cross-over framework, with multiplicity addressed by a hierarchical approach or emphasis on effect sizes and confidence intervals. An exploratory analysis will assess the effect across disease stages, including both eyes where eligible, with adjustment for inter-eye correlation.
FUNDING The study is sponsored by IRCCS Fondazione G.B. Bietti and partially funded by an unrestricted grant from OFFHEALTH, which also supplies iNAD CONTROL and placebo free of charge and has no role in study design, data collection, analysis, interpretation or publication.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
This study's planned enrollment of 60 is close to the median of 61 across 965 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →Fondazione G.B. Bietti, IRCCS is the lead sponsor of 21 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Only one eye per participant is designated as the study eye. If both eyes are eligible, the eye with the better quality visual field at screening (lower fixation losses and false-positive rates) is selected. Ocular inclusion criteria (MD, IOP, visual acuity, refraction, astigmatism) apply to the study eye only; the fellow eye must not meet any exclusion criterion that could confound interpretation of results.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants take iNAD CONTROL, 1 tablet orally once daily, for 12 weeks (Period 1), then cross over at Week 12 without a wash-out period to matching placebo, 1 tablet orally once daily, for 12 weeks (Period 2). Usual IOP-lowering glaucoma therapy continues unchanged throughout.
Dietary Supplement: iNAD CONTROL · Dietary Supplement: Placebo
Participants take matching placebo, 1 tablet orally once daily, for 12 weeks (Period 1), then cross over at Week 12 without a wash-out period to iNAD CONTROL, 1 tablet orally once daily, for 12 weeks (Period 2). Usual IOP-lowering glaucoma therapy continues unchanged throughout.
Dietary Supplement: iNAD CONTROL · Dietary Supplement: Placebo
Oral dietary supplement, 1 tri-layer tablet once daily for 12 weeks. Each tablet contains acetyl-L-carnitine hydrochloride 500 mg, nicotinamide riboside chloride 300 mg, Coleus forskohlii dry root extract titrated at 20% forskolin 75 mg (equivalent to 15 mg forskolin) and micronized hesperidin 50 mg. Gluten-free and lactose-free. Supplied free of charge by OFFHEALTH.
Oral placebo tablet, 1 tablet once daily for 12 weeks. A food product free of functional ingredients, containing only excipients, matched to iNAD CONTROL in appearance and organoleptic characteristics and packaged identically to maintain masking.
Change in PhNR Peak-to-Trough Amplitude (PhNRPT)
Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in the photopic negative response peak-to-trough amplitude (PhNRPT), defined as the distance in microvolts from the peak of the b-wave to the trough of the subsequent photopic negative response (PhNR), recorded in the study eye with photopic full-field ERG (RETeval, red flash on blue background, CD LONG protocol) after pupil dilation. The value at each timepoint is the mean of 3 consecutive ERG recordings, processed centrally by masked assessors. Higher values indicate better retinal ganglion cell function.
Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)
Change in ERG b-Wave Amplitude
Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in photopic ERG b-wave amplitude (microvolts) in the study eye, recorded with RETeval (red flash on blue background, CD LONG protocol) and processed centrally by masked assessors.
Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)
Change in ERG b-Wave Implicit Time
Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in photopic ERG b-wave latency (implicit time, milliseconds) in the study eye.
Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)
Change in Photopic Electroretinogram (ERG) W-Ratio
The reported outcome is the within-period change in the dimensionless photopic ERG W-ratio in the study eye, calculated as the end-of-period W-ratio minus the start-of-period W-ratio for each 12-week treatment period. At each assessment, a single W-ratio is calculated from the photopic ERG waveform as (b-wave amplitude - PhNR trough) / (b-wave amplitude - a-wave amplitude), where PhNR is the photopic negative response.
Time frame: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)
Change in Circumpapillary Retinal Nerve Fiber Layer (RNFL) Thickness and Ganglion Cell Complex (GCC) Thickness
Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in global circumpapillary RNFL thickness (micrometers) and macular ganglion cell complex thickness (micrometers) in the study eye, measured with spectral-domain OCT.
Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)
Change in Best-Corrected Visual Acuity (BCVA)
Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in best-corrected visual acuity in the study eye, measured with ETDRS charts and expressed as logMAR. Lower logMAR values indicate better vision.
Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)
Change in Intraocular Pressure (IOP)
Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in intraocular pressure (mmHg) in the study eye, measured with Goldmann applanation tonometry.
Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)
Change in Mean Arterial Pressure (MAP)
Change from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo) in mean arterial pressure (mmHg), calculated from systolic and diastolic blood pressure.
Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)
Proportion of Participants With a Change of at Least 1 dB in Visual Field Mean Deviation and Pattern Standard Deviation
Percentage of participants whose visual field mean deviation and pattern standard deviation in the study eye improves by at least 1 dB, and percentage whose mean deviation and pattern standard deviation worsens by at least 1 dB, from the start to the end of each 12-week treatment period (iNAD CONTROL vs placebo).
Time frame: Baseline (Week 0), Week 12 (end of Period 1) and Week 24 (end of Period 2)
Change in 24-2 Visual Field Mean Deviation (MD)
Change in visual field mean deviation (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Mean deviation is measured with Humphrey 24-2 SITA Standard and averaged across two reliable tests per visit.
Time frame: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)
Change in 24-2 Visual Field Pattern Standard Deviation (PSD)
Change in visual field pattern standard deviation (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Pattern standard deviation is measured with Humphrey 24-2 SITA Standard and averaged across two reliable tests per visit.
Time frame: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)
Change in 24-2 Visual Field Mean Light Sensitivity (MLS)
Change in visual field mean light sensitivity (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Mean light sensitivity is obtained from Humphrey 24-2 SITA Standard testing and averaged across two reliable tests per visit.
Time frame: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)
Change in 10-2 Visual Field Mean Deviation (MD)
Change in visual field mean deviation (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Mean deviation is measured with Humphrey 10-2 SITA Standard using one test per visit.
Time frame: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)
Change in 10-2 Visual Field Pattern Standard Deviation (PSD)
Change in visual field pattern standard deviation (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Pattern standard deviation is measured with Humphrey 10-2 SITA Standard using one test per visit.
Time frame: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)
Change in 10-2 Visual Field Mean Light Sensitivity (MLS)
Change in visual field mean light sensitivity (dB) in the study eye, calculated as the end-of-period value minus the start-of-period value for each 12-week treatment period. Mean light sensitivity is obtained from Humphrey 10-2 SITA Standard testing using one test per visit.
Time frame: Week 0 to Week 12 (Period 1) and Week 12 to Week 24 (Period 2)
No study locations are listed for this record.
Plan to share: No — Individual participant data will not be shared. Data ownership lies with the Sponsor (IRCCS Fondazione G.B. Bietti), and in accordance with the protocol and the EU General Data Protection Regulation (GDPR), study results will be disseminated only in anonymous and aggregated form through scientific publications.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Apr 2028, 18 months later.
Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 18 months is below that.
Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione G.B. Bietti, IRCCS